Upsher-Smith Laboratories gains approval for testosterone gel Vogelxo

MAPLE GROVE, Minn. - Upsher-Smith Laboratories on Wednesday announced that it has received final approval from the Food and Drug Administration for its new drug application for Vogelxo (testosterone) gel for topical use CIII.  

Vogelxo is a Schedule CIII androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The company is preparing to launch Vogelxo in the near future, the company stated.